Sentences with phrase «drug candidate requires»

The development of a project from target protein to potential drug candidate requires the integration of many disciplines and allows scientists to be exposed to techniques far from their own expertise or knowledge.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

This sad action maintains a 20 - year record of that Court's refusal to accept any case brought to it by a minor party or an independent candidate (not counting a 1997 case in which a Georgia Libertarian candidate challenged Georgia's law requiring candidates for state office to take a drug test).

Robotized «high - throughput screens» like this are a growing trend in drug development as they can work through massive libraries of candidate drugs quickly and accurately in a day, as opposed to the months required by manual methods.

We have the expertise and the patented technology required to develop siRNA based drug candidates internally as well as to establish fruitful collaborations with suitable partners.

A series of six cell culture assays was designed to mimic multiple old - age - associated pathways of central nervous system (CNS) nerve cell damage, and drug candidates were required to show efficacy in all of these assays before being moved forward into animals.

«The goal of the deCODE collaboration was to generate a final optimized compound with the required properties of an effective SMA drug, called a «Clinical Candidate».

A background check and pre-employment drug test will be required of the successful candidate.

A pre-employment drug screen and background check will be required of the successful candidate.

Candidates will be required to pass a pre-employment background investigation and drug test as a condition of employment.

Automating the candidate or interviewing process ---- from setting interview calendars to scheduling drug testing or background screening to on - boarding — all require messaging of some sort (and email is inefficient to process this).

In addition, most employers require candidates to pass competency exams, drug testing, and a criminal background check.

We understand background screening and drug testing is easy in Denver or Albuquerque, but returning reports quickly and locating drug testing facilities close to mines, job sites, and other rural locations can be tricky and requires a partner to keep candidates engaged and informed to streamline speed time to hire.

• Have good customer service skills • Able to follow directions and retain training • Dependable with great attendance • Stock and clean shelves • Candidates will be required to follow the below requirements: Availability Requirements: • Must be available for part - time work and commit to the full duration of the assignment • Flexible to work some Saturdays and Sundays a must Screening Requirements: • Pass Drug Screen and Background Check • Candidates with industrial and retail experience desired Adecco provides one of the most comprehensive benefits packages in the industry to contract workers.

Candidates are required to pass a drug test before beginning employment.

The successful candidate will be required to take and pass a post-offer medical examination, including drug screening, by a City physician to ensure their...

NOTE: Candidates that are offered a position are required to pass pre-employment drug and background screening.